Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q2 FY21 results · Jul–Sep 2020
Metropolis Healthcare reported revenue from operations of ₹288.35 crore (up 29.1% from Q2 FY20) and net profit of ₹60.52 crore (up 40.3% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 288.35 | 223.28 | +29.1% | 143.13 | +101.5% |
| Other income | 3.08 | 1.97 | +56.8% | 3.15 | −2.2% |
| Total income | 291.44 | 225.25 | +29.4% | 146.28 | +99.2% |
| Profit before tax | 81.39 | 53.40 | +52.4% | 3.51 | 23x |
| Net profit for the period | 60.52 | 43.13 | +40.3% | 2.88 | 21x |
| EPS, basic (₹) | 11.88 | 8.57 | +38.6% | 0.57 | 21x |
| Net margin (%) | 21.0 | 19.3 | 2.0 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 242.55 | 172.28 | +40.8% | 110.78 | +118.9% |
| Other income | 1.83 | 0.98 | +85.4% | 2.37 | −23.1% |
| Total income | 244.37 | 173.27 | +41.0% | 113.15 | +116.0% |
| Profit before tax | 70.09 | 38.09 | +84.0% | 2.07 | 34x |
| Net profit for the period | 52.36 | 31.68 | +65.3% | 2.19 | 24x |
| EPS, basic (₹) | 11.52 | 6.31 | +82.6% | 0.43 | 27x |
| Net margin (%) | 21.6 | 18.4 | 2.0 |
Consolidated
- Filed with BSE
- 12 Nov 2020, 14:44 IST
- Board meeting
- 11 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2020, 14:44 IST
- Board meeting
- 11 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE